Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Authors

Institutions

Publication Details

Journal
Annals of Medicine
Published
2024-10-28
DOI
https://doi.org/10.1080/07853890.2024.2417184
Citations
19
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
6.20
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Jorge Fernando Maspero, Nicola Brown, Robert Chan, Robert G. Price et al.
19 citations
Annals of Medicine
Asthma and respiratory diseases
6.20
article

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Jorge Fernando Maspero, Nicola Brown, Robert Chan, Robert G. Price, Ian Pavord, Peter Howarth, M Gilson
article en
19 citations

Abstract

No abstract available for this paper.
Annals of MedicineVol. 56(1)
National Institute for Health and Care Research (GB), University of Oxford (GB), Fundación para la Investigación, Docencia y Prevención del Cáncer (AR)
Good health and well-being
Openalex Percentile: Top 3%
Asthma and respiratory diseases
6.20
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.